Minted: - / 5000

4548 Sufugolix
83b504f4eaf05789eee21263d4fd9f909330391c38403ec0f5b2bba875358446

Properties

Background

Red
Bottle

Light green
Cap

Yellow
Syringe

Red
Bubbles
No
Drops
No
Label
Heart

Chemistry

Formula
C36H31F2N5O4S
Carbon
36
Polarity
Neutral

Sufugolix (, ) (developmental code name TAK-013) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) ( = 0.1 and 0.06 nM for affinity and in vitro inhibition, respectively). It was under development by Takeda for the treatment of endometriosis and uterine leiomyoma and reached phase II clinical trials for both of these indications, but was subsequently discontinued. It seems to have been supplanted by relugolix (TAK-385), which is also under development by Takeda for the treatment of these conditions and has a more favorable drug profile (including reduced cytochrome P450 inhibition and improved in vivo GnRHR antagonistic activity) in comparison.

From Wikipedia, the free encyclopedia. License: CC BY-SA.